LifeMD (LFMD) Stock Analysis & AI Equity Report
LifeMD (LFMD) overview
LifeMD (LFMD) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 194m and operating profit of USD -7.7m; the year-end share price was 3.41 USD and market capitalisation was USD 159m. LifeMD is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get LifeMD's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About LifeMD
LifeMD provides virtual medical care and pharmacy services directly to patients. Its integrated platform supports diagnosis, treatment, prescription fulfillment, and ongoing care management through technology, affiliated clinical services, and pharmacy infrastructure. The company offers virtual care in areas including primary care, men’s and women’s health, hormone health, weight management, insomnia, dermatology, and cardiology, along with prescription and over-the-counter treatments when medically appropriate.
Generate the LifeMD report
LifeMD is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for LifeMD and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on LifeMD
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.